The incidence, mortality, and risk factors of prostate cancer in Asian men

Byung Ha Chung, Shigeo Horie, Edmund Chiong

Research output: Contribution to journalReview articlepeer-review

22 Citations (Scopus)

Abstract

The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalProstate International
Volume7
Issue number1
DOIs
Publication statusPublished - 2019 Mar

Bibliographical note

Funding Information:
Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr Chung would like to report the following: honoraria and travel expenses from Astellas (Korea), Ipsen (Korea), JW Pharma (Korea), Takeda (Korea) and Janssen (USA); consultation/advisory from Janssen (Korea), Handok (Korea), Astellas (Korea), Ipsen (Korea), Amgen (Korea), Takeda (Korea) and JW Pharma (Korea); researching funding from Janssen (USA), Bayer (Germany), Pfizer (USA), Astra Zeneca (UK), Roche (Switzerland), Myovant Sciences GmbH (Australia).

Funding Information:
Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr. Chung has nothing to disclose.

Publisher Copyright:
© 2019

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'The incidence, mortality, and risk factors of prostate cancer in Asian men'. Together they form a unique fingerprint.

Cite this